Related Experiment Videos
Clinical pharmacology of the perinatal period and early infancy
1Department of Clinical Research, Synthélabo Recherche (LERS), Paris, France.
Insights
Neonatal drug kinetics are immature at birth, complicated by prenatal exposures and health conditions. Therapeutic drug monitoring is essential for safe medication in neonates and infants.
Area of Science:
- Pharmacology
- Neonatal Physiology
- Drug Metabolism
Background:
- Physiological variables regulating drug kinetics are immature at birth.
- Prenatal exposure to certain agents can alter neonatal liver and kidney excretory functions.
- Severe pathological conditions can significantly impact neonatal hemodynamics.
Purpose of the Study:
- To review available information on drug kinetics in neonates and early infancy.
- To highlight the challenges in neonatal drug therapy.
- To emphasize the importance of individualized drug administration.
Main Methods:
- Comprehensive literature review of studies on neonatal drug kinetics.
- Analysis of factors influencing drug metabolism and excretion in neonates.
- Evaluation of existing data on drug efficacy and safety in early life.
Main Results:
- Immature physiological systems lead to altered drug kinetic profiles in neonates.
- Gestational age and physiopathological status significantly influence maturation rates of drug-metabolizing and excretory pathways.
- Drug exposure in utero can further complicate neonatal drug disposition.
Conclusions:
- Neonatal drug kinetics are complex and variable.
- Therapeutic drug monitoring (TDM) is crucial for optimizing drug therapy in neonates.
- Safe and effective medication requires careful consideration of developmental and pathological factors.
Abstract:
A consistent body of data, acquired in the last 20 years, indicates that at birth most of the physiological variables regulating drug kinetics are immature, thus conditioning modified kinetic profiles in the neonate. The situation may be greatly complicated by the possible 'in utero' exposure to agents capable of altering the activity of liver and/or kidney excretory functions, and/or the presence of severe pathological conditions capable of significantly altering regional or general haemodynamics. The different variables mature at different rates depending on the gestational age and physiopathological conditions. A review of the available information on drug kinetics in the neonate and early infancy is presented here. Therapeutic drug monitoring appears to be the only possible way to assure a safer therapy for at-risk populations.